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Abstract 49 
Many heat shock proteins (HSPs) are essential to survival as a consequence of their role as 50 
molecular chaperones, and play a critical role in maintaining cellular proteostasis by 51 
integrating the fundamental processes of protein folding and degradation. HSPs are arguably 52 
amongst the most prominent classes of proteins that have been broadly linked to many human 53 
disorders, with changes in their expression profile and/or intracellular/extracellular location 54 
now being described as contributing to the pathogenesis of a number of different diseases. 55 
Although the concept was initially controversial, it is now widely accepted that HSPs have 56 
additional biological functions over and above their role in proteostasis (so called ‘protein 57 
moonlighting’). Most importantly, these new insights are enlightening our understanding of 58 
biological processes in health and disease, and revealing novel and exciting therapeutic 59 
opportunities. This theme issue draws on therapeutic insights from established research on 60 
HSPs in cancer and other non-communicable disorders, with an emphasis on how the 61 
intracellular function of HSPs contrasts with their extracellular properties and function, and 62 
interrogates their potential diagnostic and therapeutic value to the prevention, management 63 
and treatment of chronic diseases. 64 
 65 
1. Introduction 66 
The most extensively studied heat shock proteins (HSPs) are the molecular chaperones that 67 
function intracellularly in an ATP-dependent manner and include heat shock protein 60 68 
kDa/heat shock protein 10 kDa (HSP60/HSP10; chaperonins) (HSPD/HSPE); HSP40 (DNAJ), 69 
HSP70 (HSPA); HSP90 (HSPC); HSP100; and HSP110 (HSPH) families. The expression of 70 
many of these HSP is regulated by heat shock transcription factors (HSF), of which HSF1 is 71 
the best studied. Increasing evidence now suggests that these molecular chaperones also 72 
have biological properties in the extracellular environment which may be independent of their 73 
chaperone functions. In addition to ATP, the molecular chaperone activity of the major HSPs 74 
is regulated by a cohort of non-substrate accessory proteins, known as co-chaperones. Co-75 
chaperones are a diverse group of chaperone regulatory proteins which are required, to a 76 
greater or lesser degree, by certain chaperones. HSP90, for example, has over 20 co-77 
chaperones that fine tune its function and adapt it to the different stages of the protein folding 78 
pathway. Some HSP families, such as HSP40, include members having both chaperone and 79 
co-chaperone activity.   80 
 81 
A particularly lively area relates to the evolving insight into the therapeutic potential of targeting 82 
HSPs in cancer, and their value as an exciting class of molecular target. Although HSPs and 83 
their transcription factors have been the subject of sustained interest in the field of cancer 84 
biology, more recently they have been attracting interest in many other chronic conditions such 85 
as diabetes, obesity, autoimmune disease, neurodegeneration, muscular dystrophies, 86 
psychiatric disorders and chronic heart failure. These studies are revealing that although 87 
increased levels of intracellular HSPs may be beneficial for acute conditions, such increases 88 
can be detrimental for certain chronic conditions, as exemplified by acute and chronic heart 89 
conditions. The contribution of extracellular HSPs to chronic disease is poorly understood. 90 
Increased levels of extracellular HSPs appear to be detrimental by enhancing inflammation 91 
pathways, and hence for conditions such as diabetes a reduction in the ratio of extracellular 92 
to intracellular HSPs is beneficial. In contrast, extracellular HSPs can also be beneficial to 93 
certain autoimmune conditions as a consequence of their ability to engage with, and recruit 94 
the immunomodulatory activity of regulatory T cell populations. Although the reported 95 
dichotomies in functionality of HSPs would appear to be counter-intuitive and has been the 96 
subject of great debate and counter-arguments, one needs to consider the context and the 97 
temporal nature of disease and its control. What is clear from current knowledge is that HSPs 98 
play important biological roles under physiological, stressful and disease conditions.  99 
 100 
The articles in this theme issue highlight how insights (both anticipated and unanticipated) into 101 
the biological function of HSPs in cancer have revealed new therapeutic options for the 102 
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treatment of the disease. The issue also explores how the intracellular function (ATP-rich 103 
context) of HSPs contrasts with their extracellular function (ATP-poor context), and their 104 
potential diagnostic and therapeutic value to the prevention, management and treatment of 105 
chronic diseases. Here we integrate and critique the content of this theme issue, addressing 106 
HSP moonlighting in the context of their contrasting intracellular and extracellular roles. 107 
 108 
2. Heat shock proteins and protein moonlighting 109 
Although the finding that exposure to a non-physiological temperature (37°C versus 26°C) 110 
induced a new puffing pattern in the polytene chromosomes of Drosophila [1] was interesting, 111 
the author could not have anticipated the significance and broad reach of this finding, 112 
especially given that the ‘biological relevance of the findings were unclear’ and it proved 113 
difficult to publish the findings. However, over 50 years later, we continue to appreciate the 114 
importance of this heat shock response (HSR) to the maintenance of cellular homeostasis and 115 
protection against a multitude of physical, chemical and biological stressors that exist in the 116 
environment [2]. 117 
 118 
As the protein folding paradigm and molecular chaperone functions of HSPs were developing 119 
in the late 1980s and 1990s, it became apparent that some of these proteins were also present 120 
on the surface of cells or in the extracellular fluids. This contradicted the established dogma 121 
that these proteins were exclusively intracellular and so it took time for the data to be accepted, 122 
the findings to gain traction with the scientific community and for this new field of extracellular 123 
HSPs to be accepted and become established. Interest in the biological role(s) and functions 124 
of these proteins grew, as did interest into the potential capacity of extracellular HSPs to 125 
influence biology and physiology. As discussed in this issue, it was shown that the treatment 126 
of cells with purified HSPs resulted in cell activation similar to that induced by pro-inflammatory 127 
cytokines. Despite controversy surrounding the possibility that at least some of the pro-128 
inflammatory effects of HSPs might be due to contaminants of the preparations that have been 129 
used [3, 4], there is also a wealth of evidence from a number of settings which argues against 130 
this concept [5]. 131 
 132 
A new paradigm that at least some HSPs are secreted proteins [6] with pro- (HSP60, HSP70, 133 
HSP90) or anti-inflammatory (HSP10, thioredoxin, HSP27, BiP) actions of importance in 134 
human diseases such as cancer, coronary heart disease, diabetes and rheumatoid arthritis 135 
[7], to name but a few, has therefore arisen. In addition to having direct effects on cells, HSPs 136 
can bind peptides and present them to T cells to modulate immune responses, and this might 137 
have implications in a number of disease settings, including cancer [8]. It has become 138 
apparent that HSP70 can be present in a membrane expressed form. The significant 139 
diagnostic, therapeutic and imaging potential of this finding, and the progress which has been 140 
made in exploiting membrane HSP70-based theranostics (i.e. combining diagnostic and 141 
therapeutic capabilities into a single agent; a key element of Precision Medicine) for the 142 
management and treatment of patients with cancer, is considered in detail by Multhoff and 143 
colleagues in this issue.  144 
 145 
Taken together, the findings that HSPs can be present in the extracellular and cell-associated 146 
compartments have led to the establishment of a new paradigm which designates these 147 
proteins as ‘moonlighting proteins’ (proteins with more than one function) that have the 148 
capacity to ‘escape’ from cells and interact with different cell types to elicit a range of biological 149 
effects. These proteins can even act as receptors for inflammatory mediators called 150 
‘inflammogens’ [9]. Support for this new paradigm comes from a number of studies that are 151 
highlighted by Pockley in this issue, and a large number of studies that have, and continue to 152 
reveal, the presence of a number of HSPs in the bodily fluids of man and animals [10]. The 153 
first two contributions in this issue provide a critical overview of extracellular HSPs (by 154 
Pockley) and the biology of protein moonlighting (by Jeffery). 155 
 156 
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3. Intracellular versus extracellular heat shock proteins in cancer  157 
The initiation, progression and metastasis of cancer have all been shown to be accompanied 158 
by multiple cellular insults arising from both intracellular and extracellular sources. Internal to 159 
the cancer cell, the high expression of oncogenic proteins (many of which are mutated), 160 
altered cellular metabolism, aneuploidy and genomic instability all contribute to its 161 
characteristic stressed phenotype. Moreover, during cancer development, cells are exposed 162 
to altered extracellular conditions that can include hypoxic, acidotic, mechanical and nutrient 163 
deprived microenvironments, further stimulating the cancer cell to engage highly conserved 164 
survival pathways such as the HSR. Consistent with the knowledge that cancer cells are 165 
exposed, both internally and externally, to major proteotoxic insults that challenge cellular 166 
homeostasis and survival, it is not surprising to find that cancers constitutively express high 167 
levels of HSP family members. In fact, tumour cells have become to be regarded as addicted 168 
to HSPs (e.g. HSP90) as well as their transcriptional regulators (e.g. HSF1).  169 
 170 
Increased expression of many HSPs, including HSP27 (HSPB1), HSP72 (HSPA1A, HSPA1B) 171 
and HSP90 (HSP90AA1, HSP90B1), have been shown in a wide variety of cancer types such 172 
as breast, prostate, lung and melanoma, and are associated with poor patient outcomes. 173 
Moreover, HSF1, the master regulator of the HSR has also been shown to be increased in 174 
expression and constitutively activated in many cancers. The parallel molecular, genetic and 175 
pharmacological investigations that have been performed in relation to HSPs and their 176 
signalling and transcriptional regulation, has further confirmed their importance to the growth 177 
and progression of many tumour types (reviewed by Calderwood and colleagues in this issue). 178 
For example, the work in targeting and developing HSP90 inhibitors has confirmed the 179 
importance of HSP90 to cancer signalling and oncogene driven growth (reviewed by Neckers 180 
and colleagues in this issue). In a similar manner, the HSR has been shown to be an integral 181 
part of the oncogenic network, working through the actions of HSF1 to maintain cancer cell 182 
survival and function (reviewed by Dai in this issue). Interestingly, it has been shown that 183 
within the oncogenic context, the expression of HSF1 is indispensable for the growth and 184 
survival of cancer cells, while its loss in non-transformed cells has little to no effect [11]. 185 
 186 
HSF1 and many of the HSPs have been shown to play fundamental roles in many aspects of 187 
the cancer cell phenotype associated with the hallmarks of cancer [12] including sustained 188 
proliferative signalling, evading growth suppression, replicative immortality, angiogenesis, 189 
resisting cell death and supporting invasion and metastasis [13]. Moreover, they are also 190 
involved in a number of the more recently identified hallmarks of cancer such as the 191 
deregulation of cellular energetics, genome instability, avoiding immune destruction and 192 
enabling tumour-promoting inflammation. The wide-ranging actions of the HSPs and HSF1 193 
are not limited to the cancer cells themselves, but have also been shown to play important 194 
roles for accessory cell function within the tumour microenvironment such as the cancer 195 
associated fibroblasts (CAFs) and tumour associated macrophages (TAMs), ultimately 196 
contributing to cancer cell growth and progression [14].  197 
 198 
Although it was originally proposed that the actions of HSPs were primarily intracellular to 199 
cancer cells and other cells of the tumour microenvironment, it is now evident that their 200 
presence and functionality are also very important to many molecules and processes external 201 
to the cell. For example, HSP90α (HSP90AA1) is known to exist outside the cell, termed as 202 
eHSP90, and has been shown to interact with a number of client proteins, including matrix 203 
metalloproteinase 2 (MMP2) through which it enhances the migration and invasion of cancer 204 
cells (reviewed by Neckers and colleagues, and by Calderwood and colleagues in this issue). 205 
It has been shown that the functions of extracellular HSPs can have both anti-tumour or pro-206 
tumour effects, ranging from anti-tumour or pro-tumour immunomodulation (HSP90, HSP72, 207 
HSC70, HSP60, HSP27), suppression or promotion of tumour cell proliferation (GRP78, 208 
HSP20, HSP27), as well as promotion of cancer cell invasion (HSP90, GRP75, HSP27) and 209 
angiogenesis (HSC70)[15-20]. Moreover, co-chaperones of HSP90, such as the 210 
HSP70/HSP90 organising protein (HOP), HSP40 and p23 have also been shown to be 211 
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extracellular, and similar to their role internal to the cell, are in complex with HSP90 to illicit 212 
extracellular functions such as MMP-2 activation and cancer cell invasion and migration [17, 213 
21]. 214 
 215 
Our increasing knowledge of the unique roles of HSPs and their co-chaperones external to 216 
the cell is leading to novel approaches for the therapeutic targeting of cancers. For example, 217 
cell surface HSP70 is currently being used as a target of novel therapies that include 218 
nanoparticle-based treatments for cancer (reviewed by Multhoff and colleagues in this issue), 219 
and cell-impermeable HSP90 inhibitors are being examined as to their efficacy in inhibiting 220 
cancer migration and invasion (reviewed by Multhoff and colleagues in this issue). Therefore, 221 
our increased understanding of the actions of extracellular HSPs will not only lead us to a 222 
better understanding of the biology of cancer and its progression, but will also reveal further 223 
therapeutic opportunities for the treatment of advanced cancers. 224 
 225 
4. Intracellular versus extracellular heat shock proteins in chronic diseases 226 
Much of the research into the function of HSPs in chronic disease has been focussed on 227 
cancer. However, it is also clear that HSPs are involved in many other chronic conditions, from 228 
neurological and muscle-wasting disorders to obesity and post-traumatic stress. This range of 229 
chaperonopathies highlights the important and central role which these proteins play in 230 
maintenance of correct cellular function.  231 
 232 
Findings from experimental, pharmacological or exercise studies on changes to HSP72 233 
expression levels suggest that the manipulation of the extracellular to intracellular ratio of HSP 234 
levels represents a useful avenue for the prevention and treatment of diabetes (reviewed by 235 
Geiger and colleagues in this issue). For example, there is evidence that exercise promotes 236 
the release of extracellular HSP72 from certain human cells (brain, [22]; epithelium, [23]; 237 
immune system, [24]; muscle and adipose tissue, [25]). However, long-term exercise 238 
promotes a decrease in extracellular HSP72 and an increase in intracellular skeletal muscle 239 
HSP72 (reviewed by Geiger and colleagues in this issue). In fact, it is now apparent that the 240 
balance of extracellular (pro-inflammatory) versus intracellular (anti-inflammatory) HSP72 241 
appears to be a determining factor for the extent of tissue inflammation and hence the 242 
pathology associated with diabetes. It is hypothesised that interventions that lower the 243 
extracellular to intracellular HSP72 ratio are potentially beneficial in the context of diabetes 244 
progression [26]. Hence, carefully constructed exercise regimes that favourably modulate this 245 
HSP72 ratio may serve as powerful therapeutic interventions for the prevention and 246 
management of diabetes. However, more detailed studies on extracellular HSPs and the 247 
effects of exercise are needed, particularly the contribution of different tissues to extracellular 248 
HSP expression levels, and the biochemical and physiological mechanisms of action of these 249 
HSPs.      250 
 251 
HSPs, and HSP72 in particular, also play an important role in muscle function. HSP90, HSP72, 252 
and HSP27 all have a pro-myogenic role in muscle development, albeit via distinct 253 
mechanisms. HSPs are also differentially expressed in the muscle progenitor pool that 254 
differentiates to give rise to new muscle tissue. HSP72 is the most widely studied HSP in this 255 
context and is required for muscle repair after acute injury. Both intracellular and extracellular 256 
HSP72 contribute to this process, with extracellular HSP72 functioning primarily via the 257 
activation of the immune response. Interestingly, many of the effects of HSP72 knockout on 258 
muscle regeneration involve the immune response, which suggests that, given that 259 
extracellular HSP72 arises from intracellular HSP72, the extracellular functions of HSP72 are 260 
more important in this context. Indeed, injection of extracellular HSP72 has been shown to 261 
ameliorate many of the effects of muscle injury in HSP72 null mice [27]. With respect to 262 
disease, over-expression of intracellular HSP72 had a positive effect and led to improvements 263 
in body strength and endurance, diaphragm health, normalised muscle force and reduced 264 
markers of muscle damage in a mouse model of Duchenne Muscular Dystrophy [28]. HSP72 265 
also has a positive effect on muscle function in the context of muscle immobilisation, 266 
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suggesting that over-expression of this protein may be a therapeutic approach for a range of 267 
muscle wasting conditions. Although it has not been demonstrated, it is likely that at least 268 
some of the described functions of HSP72 in these conditions are attributed to the extracellular 269 
function.  270 
 271 
In addition to a role in muscle-related immune responses, experimental models have provided 272 
evidence that both intracellular and extracellular HSPs also have a protective function in 273 
autoimmune diseases. The application of exogenous extracellular recombinant HSPs and the 274 
experimental co-induction of endogenous intracellular HSPs have been shown to lead to 275 
production of disease protective regulatory T (Treg) cells ([29]; reviewed by van Eden in this 276 
issue). This has stimulated research into the development of therapeutic HSP-based peptide 277 
vaccines for the restoration of immune tolerance in inflammatory diseases. 278 
 279 
There is emerging evidence for increased expression of extracellular HSP70, HSP90, and 280 
certain associated co-chaperones (e.g. BAG-3) in heart failure, and that their functions are 281 
complementary and independent of their intracellular isoforms. The important therapeutic and 282 
diagnostic considerations of these findings are reviewed by Willis and colleagues in this issue. 283 
Current findings suggest that therapeutic strategies involving the increase of HSP levels may 284 
be applicable in the context of acute heart conditions (e.g. acute myocardial 285 
infarction/ischemic reperfusion injury), but not chronic heart conditions (e.g. hypertension). 286 
Indeed, the pharmacological enhancement of intracellular HSP function has been shown to 287 
provide protection against experimental myocardial infarction [30]. With respect to chronic 288 
heart conditions, extracellular and intracellular HSPs exert different effects. For example, a 289 
decrease in the expression of intracellular HSP70 promotes cardiomyocyte hypertrophy and 290 
dysfunction while protecting animals from cardiac fibrosis development, whereas inhibition of 291 
extracellular HSP70 has been shown to improve hypertension-induced hypertrophy and 292 
fibrosis [31]. In the context of chronic heart disease, there are some parallels in the findings 293 
for extracellular HSP90 and extracellular HSP70. For example, the decrease in fibronectin 294 
levels, collagen production and the associated TGFβ signalling pathway via the inhibition of 295 
extracellular HSP90 [32, 33] has implications for the fibrosis-related pathology of chronic heart 296 
conditions. Although there is great promise for extracellular HSP70 and HSP90 as diagnostic 297 
markers of chronic heart disease, a deeper understanding of the mechanism(s) of action of 298 
extracellular HSP70 and HSP90 and its co-chaperones is required before effective prevention 299 
and treatment can be achieved. 300 
 301 
HSPs are also important in the context of neurodegeneration and neurological dysfunction 302 
leading to psychiatric diseases. HSP40s are the largest and most diverse of the HSPs and 303 
changes in different HSP40 isoforms all give rise to different, but related forms of 304 
neurodegeneration (reviewed by Cheetham and colleagues in this issue). Although these 305 
HSP40 isoforms share structural features such as the J domain, they also contain a number 306 
of unique functional domains (particularly since most of the isoforms associated with disease 307 
are the more diverse type III HSP40/DNAJC). The redundancy between isoforms in some 308 
contexts can also explain why it is possible to ameliorate the disease consequences of a 309 
mutation or deficiency of one isoform via over-expression of another. For example, 310 
overexpression of DNAJA1 can suppress aggregation of polyQ ataxin associated with 311 
neurodegeneration [34]. Interestingly, there are no neurological disorders associated with 312 
mutations in type I HSP40s like DNAJA1, presumably because many of these proteins are 313 
essential and loss of function cannot therefore be tolerated. With respect to psychiatric 314 
disorders, the co-chaperone FKBP51, acting via HSP90, is both a causative agent and 315 
biomarker for various forms of the disease (reviewed by Blair and colleagues in this issue). 316 
Increased levels of FKBP51 lead to glucocorticoid resistance by retarding the recruitment of 317 
glucocorticoid receptor (GR) to the nucleus and perturbing signalling via the hypothalamic-318 
pituitary-adrenal (HPA) axis that culminates in a poor stress coping phenotype (reviewed by 319 
Blair and colleagues in this issue). Specific single nucleotide polymorphisms that result in 320 
methylation changes which alter levels of FKBP51 may be a risk or prognostic factor for 321 
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anxiety or suicide risk [35, 36].  This suggests that modulation of FKBP51 levels may be a 322 
relevant therapeutic strategy. However, in the context of both HSP40-related 323 
neurodegeneration and FKBP51-related psychiatric disorders, we have limited understanding 324 
of the relative contribution of intracellular versus extracellular forms of the relevant HSPs due 325 
to a paucity of data. Certainly, it is known that both HSP70 and HSP90 are extracellular and 326 
therefore it is at least theoretically possible that co-chaperones of these two proteins (HSP40 327 
and FKBP51) also exist in functional extracellular forms. In these examples, what we do know 328 
is that disease is usually associated with a change in the levels of a particular HSP. For 329 
example, mutations or deletions in the HSP40 isoform DNAJC29 is one of the most common 330 
causes of ataxia [37]. In some instances, the change in HSP levels are associated with 331 
missense mutations, deletions or splicing changes, while in other cases levels change in 332 
response to the environment (such as age-induced increases in FKBP51 levels which are 333 
associated with psychiatric disorders).  334 
 335 
5. Conclusion 336 
Fundamental insights into how HSPs give rise to disease will be an important component of 337 
therapeutic targeting of these proteins. However, many knowledge gaps remain and need to                              338 
be addressed. Importantly, with cancer and autoimmune disease being the exceptions, there 339 
is limited insight into the role played by extracellular HSPs in chronic diseases such as 340 
neurodegeneration or psychiatric disorders. In addition, while much is known about the 341 
mechanism of action of specific intracellular HSP networks, such as the HSP90-HOP-HSP70 342 
or HSP70-HSP40 complexes, the genesis and function of these HSP complexes in the 343 
extracellular milieu is poorly understood and raises many fundamental questions that need to 344 
be answered before therapeutic applications can be properly developed. Like the HSPs they 345 
regulate, co-chaperones like HOP appear to also be secreted via exosomes [38]. However, it 346 
is not known if HOP is secreted together with HSP90 and HSP70 as a functional complex, or 347 
if it is secreted separately and then forms a complex with the HSPs [39]. Therefore, the major 348 
questions that need to be answered for these extracellular HSP complexes and many other 349 
extracellular HSPs include the following: 350 
 351 
1. What is the origin of extracellular HSPs, and which isoforms are structurally and 352 
functionally distinct from their intracellular counterparts, and which isoforms are 353 
derived from their intracellular counterparts? 354 
2. Which isoforms of extracellular HSPs are encoded by separate genes and which are 355 
encoded by splice variants of the same gene? 356 
3. Are there always receptors associated with extracellular HSPs? 357 
4. As a general principle, is the ratio of extracellular to intracellular HSP levels important 358 
for cellular and physiological homeostasis? 359 
5. What stimuli, mechanisms and pathways are required for the secretion of extracellular 360 
HSPs? 361 
6. Do extracellular HSPs function as molecular chaperones, is their activity regulated by 362 
extracellular co-chaperones and what defines extracellular client proteins? 363 
 364 
While there is much work to be done before we can more fully define the true biological role, 365 
therapeutic potential and significance of extracellular HSPs, we can draw inspiration from 366 
Hippocrates who stated: ‘That which drugs fail to cure, the scalpel can cure. That which the 367 
scalpel fails to cure, heat can cure. If the heat cannot cure, it must be determined to be 368 
incurable’. 369 
 370 
  371 
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